New Understanding, Strategies and Tools for Delivering · 1:50 Low Intensity Pulsed Focused...

FINAL WEEKS TO REGISTER!

A Division of Cambridge Innovation Institute

Blood-Brain BarrierJune 15-16, 2016 • Westin Boston Waterfront, Boston, MA

Final Agenda

2nd Annual

New Understanding, Strategies and Tools for Delivering Therapy to the Brain

Event Features:

• Understanding and Utilizing Mechanisms of the BBB

• Understanding and Predicting Brain Penetration

• Delivering Therapies Across the BBB

Recommended Short Course:

Molecular Imaging of the Blood-Brain Barrier

Keynote Presentation:

BBB Breakdown in Neurodegenerative Diseases: Contributions to Disease Pathogenesis and Implications for Drug Delivery

Berislav Zlokovic, M.D., Ph.D., Director, Zilkha Neurogenetic Institute, Keck School of Medicine

WorldPreclinicalCongress.com/Blood-Brain-Barrier

WORLD PRECLINICALCONGRESS

Part of

Where Preclinical Minds Meet Discovery Technologies

PREMIER SPONSORS

https://chidb.com/reg/wpc/reg.asp

http://www.WorldPreclinicalCongress.com/Blood-Brain-Barrier


2 | World Preclinical Congress WorldPreclinicalCongress.com/Blood-Brain-Barrier

Conference-at-a-Glance* *Separate registration required for Short Courses and Symposia

Hotel & Travel Information

CONFERENCE VENUE AND HOTEL:Westin Boston Waterfront425 Summer St.Boston, MA 02210T: 617-532-4600

Go to the travel page of www.WorldPreclinicalCongress.com for additional info

RESERVATIONS:

Go to the travel page of www.WorldPreclinicalCongress.com

Room Rate: $309 s/dRes Cutoff: May 16, 2016

Wednesday - Thursday, June 15-16 Thursday - Friday, June 16-17

Novel Preclinical Models in Oncology Tumor Models for Cancer Immunotherapy

Cancer Immunotherapy and Combinations Translational Gene Editing

New Approaches for Predicting Drug Toxicity 3D Cellular Models

Advances in iPS Cell Technology for Drug Development Applications

Chemical Biology in Drug Discovery

Mastering Medicinal Chemistry Property-Based Drug Design in Medicinal Chemistry

Blood-Brain Barrier Targeting Membrane Proteins

Training Seminar: Applying Pharmacology to New Drug Discovery

Plenary Keynote Program - Thursday, June 16, 1:45 – 3:30 pm

Dinner Short Courses* - Thursday, June 16, 7:00 – 9:30 pm

Tuesday, June 14

Pre-Conference Short Courses* Tuesday, June 14, 8:00 – 11:00 am Tuesday, June 14, 12:00 – 3:00 pm Tuesday, June 14, 3:30 – 6:30 pm

Latest Advances in Nano-Oncology Symposium*Tuesday, June 14, 8:00 am – 5:00 pm

Oncolytic Viruses in Cancer Therapies Symposium*Tuesday, June 14, 8:00 am – 5:00 pm

Plenary Keynote ProgramJune 16, 1:45 - 3:00 pm

PLENARY KEYNOTE PRESENTATIONS:

Insights on Innovative Approaches to Transform Drug DiscoveryKeynote Speakers:

Anthony J. Coyle, Ph.D., CSO and Senior Vice President, Centers for Therapeutic Innovation, Pfizer Inc.

James Wilson, M.D., Ph.D., Professor of Medicine and Pediatrics, Perelman School of Medicine; Director, Orphan Disease Center and Director, Gene Therapy Program, University of Pennsylvania

June 16, 3:00 - 3:30 pm

PLENARY KEYNOTE PANEL: Insights on Innovative Technologies Enabling Preclinical ResearchPanelists:

Matt Gevaert, Ph.D., CEO and Co-Founder, KIYATEC

Other Panelists to be Announced (Sponsorship Opportunities Available)

Amit Vasanji, Ph.D., CTO & CSO, ImageIQ

Tim Robertson, Ph.D., CEO, Vium, Inc.






Present a Poster and SAVE $50!Cambridge Healthtech Institute encourages attendees to gain further exposure by sharing their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by April 22, 2016.

Register online, or by phone, fax or mail. Please indicate that you would like to present a poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract using our online abstract submission tool. Please see the website for more details.

Reasons you should present your research poster at this conference:

• Your poster will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions

• Receive $50 off your registration

• Your poster abstract will be published in our conference materials

PREMIER SPONSORS

CORPORATE SUPPORT SPONSORS

CORPORATE SPONSORS








SHORT COURSES

Student Fellowship

*June 16, 2016 | Boston, MA

*Separate Registration Required

SC10: Molecular Imaging of the Blood-Brain BarrierIn this short course, we will discuss the development and application of molecular imaging techniques for brain research. The course will include introduction of molecular imaging, how to design chemical probes to cross the blood-brain barrier for neuroimaging, the application of novel and existing neuroimaging tools for brain research, and CNS drug discovery. Instructors:Changning Wang, Ph.D., Instructor, Radiology, Massachusetts General Hospital/Harvard Medical SchoolMarco L. Loggia, Assistant Professor of Radiology, Harvard Medical School, Associate Director, Center for Integrative Pain NeuroImaging, A. A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital Xiaoyou Ying, Ph.D., Head, Bioimaging, DSAR US, Preclinical Safety, Sanofi US






2nd Annual

Blood-Brain Barrier

June 15-16, 2016 | Boston, MA

New Understanding, Strategies and Tools for Delivering Therapy to the Brain

Recommended All Access Package:June 14 SC10: Molecular Imaging of the Blood-Brain Barrier*June 15-16: Blood-Brain BarrierJune 16-17: Property-Based Drug Design in Medicinal Chemistry* Separate registration required.

WEDNESDAY, JUNE 15

7:00 am Registration and Morning Coffee

UNDERSTANDING AND UTILIZING MECHANISMS OF THE BBB

8:25 Chairperson’s Opening RemarksRobert D. Bell, Ph. D., Principal Scientist, Integrative Neuroscience, Pfizer

»8:35 KEYNOTE PRESENTATION: BBB BREAKDOWN IN NEURODEGENERATIVE DISEASES: CONTRIBUTIONS TO DISEASE PATHOGENESIS AND IMPLICATIONS FOR DRUG DELIVERY

Berislav Zlokovic, M.D., Ph.D., Director, Zilkha Neurogenetic Institute, Keck School of MedicineThe blood-brain barrier (BBB) limits the entry of neurotoxic blood-derived products, pathogens and cells into the central nervous system (CNS) and in the same time restricts delivery of most therapeutic agents to the CNS. The BBB is damaged in Alzheimer’s disease (AD) and other neurodegenerative disorders, and in models of these neurodegenerative disorders. We will discuss contributions of BBB breakdown to disease pathogenesis and implications for CNS drug delivery.

9:05 Characterization of the Non-Conventional Blood Meningeal Barrier and Its Role during Homeostasis and NeuroinflammationJorge Alvarez, Ph.D., Assistant Professor, Pathobiology, University of PennsylvaniaUsing novel human in vitro models of the BBB and BMB, we found that their inherent barrier properties are differentially influenced by astrocyte-secreted

factors. Careful examination of these CNS barrier sites will advance our understanding of the mechanisms regulating barrier function and underlying the development of neuroinflammation.

9:35 Predictive Understanding of Blood-Brain Barrier Transport Mechanisms to Counter Chemical and Biological Weapons ThreatsBrian Pate, Physical Scientist, Chemical and Biological Technologies Department, Defense Threat Reduction AgencyThe essential protective nature of the blood-brain barrier challenges development of centrally acting medical countermeasures to chemical and biological weapons. Recent efforts driven by the U.S. Department of Defense have exploited multifaceted toolsets to foster new models and understanding of selective human blood-brain barrier transport pathways and their molecular, cellular, and systemic modulation within baseline and induced dynamic biochemical environments.

10:05 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

10:50 Regionally Distinct Astrocyte Interferon Signaling Promotes Blood-Brain Barrier (BBB) Integrity during Neurotropic Viral InfectionRobyn S. Klein, M.D., Ph.D., Professor, Internal Medicine, Pathology & Immunology, Anatomy & Neurobiology, Washington University School of MedicineWe demonstrate that type I interferon receptor (IFNAR) signaling in astrocytes regulates BBB permeability and protects the cerebellum from infection and immunopathology. Interferon stimulated genes (ISGs) had higher basal and interferon-induced expression in human and mouse cerebellar astrocytes compared to cortical astrocytes. Our data identify cerebellar astrocytes as key responders to viral infection and highlight distinct innate immune responses in astrocytes from evolutionarily disparate regions of the CNS.

11:20 Adhesion Molecules of the BBB and NeuroinflammationAlexandre Prat, M.D., Ph.D., FRCPC, Professor, Neuroscience, Université de MontréalThis presentation will provide a short overview of the progresses that were made over the last 5 years to identify novel pathways that are involved in the selective recruitment of specific immune cells to the CNS and in the process of CNS immune quiescence. These molecules are currently seen as the basis for the development of future therapies in neuroinflammatory disorders, including multiple sclerosis.






11:50 In vivo Microscopy-Based Assay for Brain Sponsored by Distribution of Biologics: From a Case-Study to the Industry StandardLeonard Khiroug, CSO, Neurotar Ltd.Conventional brain exposure assays either lack longitudinality (IHC and ELISA) or have low spatial resolution insufficient for separation of cellular/subcellular compartments (radiolabelled imaging and microdialysis). Neurotar’s in vivo microscopy assay overcomes these limitations by quantitatively imaging brain exposure of fluorescently labelled biologics in living mouse’s cortex with sub-micrometer resolution.

12:05 Sponsored Presentation (Opportunity Available)

12:20 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:50 Session Break

UNDERSTANDING AND PREDICTING BRAIN PENETRATION

1:40 Chairperson’s RemarksWilliam Elmquist, Pharm.D., Ph.D., Professor, Pharmaceutics, University of Minnesota

1:50 Low Intensity Pulsed Focused Ultrasound and Microbubbles Results in Sterile Inflammatory Response in the Rat BrainZsofia Kovacs, Ph.D., Postdoctoral Fellow, Radiology and Imaging Sciences, National Institutes of HealthVery little is known about the graded cellular and molecular responses in the brain following pFUS coupled with MB exposures through the disruption of the BBB (BBBD). Proteomic changes in the brain associated with BBBD indicate that pFUS + MB rapidly effects to the cerebral vasculature as evident by BBBD, in addition to the shockwave from MB collapse, induces mild stress within various cellular elements in the neurovascular unit.

2:20 Imaging of BBB Opening Induced by UltrasoundKullervo Hynynen, Ph.D., Professor, Medical Biophysics, University of TorontoUltrasound combined with intra-vascular microbubbles can be used to focally and temporarily open the BBB in image guided locations. We have explored the use of MRI, ultrasound, and two-photon imaging to detect, study, and monitor the opening. In this presentation, our experience with these methods will be reviewed and potential applications discussed.

2:50 Refreshment Break in the Exhibit Hall with Poster Viewing

3:35 Pharmacokinetics of CNS PenetrationAndreas Reichel, Ph.D., Vice President, Head, Research Pharmacokinetics, Bayer PharmaWhile target site concentrations in most peripheral organs are in direct correspondence with unbound plasma concentrations, this may not be the case for targets within the CNS due to the existence of the blood-brain barrier. The talk

will focus on the PK parameters and PK processes which are key in controlling the unbound concentrations in brain as most relevant effect compartment for CNS drug efficacy.

4:05 Using in vitro Transporter Studies and Preclinical Animal Models to Predict Brain Penetration of P-gp and BCRP Substrates in HumansBo Feng, Ph.D., Senior Principal Scientist, Pharmacokinetics, Dynamics, and Drug Metabolism, Pfizer, Inc.It has been a big challenge to predict brain penetration of efflux transporter substrates in humans. This presentation will discuss species differences of efflux transporters at blood-brain barrier and what the predictability of preclinical species is, including rat and monkey. Additionally, the relationship between CSF and unbound brain concentrations of brain transporter substrates in monkey and the translation to humans will be discussed.

4:35 Translational Strategy for Predicting Brain Penetration: From in vitro Transporter Data to Human Brain DistributionPatrick Trapa, Ph. D., Lead, PDM Neuroscience Quantitative Translation, PfizerAccurate prediction of brain penetration requires the incorporation of in silico, in vitro, and in vivo approaches. Physiologically based pharmacokinetic modeling reduces the complexity of the blood-brain barrier to a simplified framework and integrates the key information. This presentation outlines the high-throughput methodology in place at Pfizer.

5:05 Three-Dimensional Dynamic Blood-Brain Barrier ModelMonica Moya, Ph.D., Research Engineer, Materials Engineering Division, Lawrence Livermore National LaboratoryCurrent in vivo models of the BBB pose interspecies differences while traditional in vitro models using transwells fail to capture actual in vivo permeability rates and lack physiological relevance. We have developed a dynamic microfluidic 3D human cell culture platform to more accurately investigate compound permeability from the bloodstream to the CNS using a second on-chip platform we have also developed. This talk will describe our BBB model and focus on the drug clearance and interaction with our second CNS on chip platform.

5:35 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 Close of Day

THURSDAY, JUNE 16

7:00 am Registration

7:30 Interactive Breakout Discussion Groups with Continental BreakfastThis session features various discussion groups that are led by a moderator/s who ensures focused conversations around the key issues listed. Attendees choose to join a specific group and the small, informal setting facilitates sharing of ideas and active networking. Continental breakfast is available for all participants. Details on the topics and moderators are available on the conference website.

June 15-16, 2016 | Boston, MABlood-Brain Barrier






DELIVERING THERAPIES ACROSS THE BBB

8:35 Chairperson’s RemarksPer-Ola Freskgard, Ph.D., Vice Director and Senior Leader, Neuroscience, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.

8:45 Safely Crossing the BBB: How Do Cells Manage to Do It?Lois A. Lampson, Ph.D., Associate Professor of Neurosurgery, Brigham & Women’s Hospital, Harvard Medical SchoolDelivering therapy across the BBB faces two kinds of challenges. One challenge is the BBB itself. A different kind of challenge is that modulation of the BBB must be well-regulated. Indeed, regulatory balance is a general concern, as seen, for example, with immunotherapy. Intriguingly, blood-borne cells are able to meet both challenges: to enter the brain, safely. Considering how cells do this can give both technical and conceptual insight as we consider alternative approaches to delivering therapy across the BBB.

9:15 Novel Human Stem Cell-Derived in vitro BBB Model and Its Utility in Evaluating CNS-Targeting BiologicsMahmud Bani, Ph.D., Team Leader, Senior Research Officer, Translational Bioscience, National Research Council CanadaWe have developed and characterized a human amniotic fluid-iPSC-derived in vitro model, which reproduces salient molecular and functional features of the blood-brain barrier (BBB), including high TEER, polarization of transporters, and modulation by ‘brain’ microenvironment. This model is useful for assessing the transport of both synthetic and biologic CNS-targeting therapeutics. In particular, we have characterized the transport of various antibodies against receptors that undergo receptor-mediated transcytosis (Molecular Trojan Horses), and their ability to deliver various cargos.

9:45 Blood-Brain Barrier Penetrating IgG-Fusion Proteins for the Treatment of Human Lysosomal Storage DisordersRuben Boado, Ph.D., Vice President, R&D, Cofounder, ArmaGenLysosomal enzymes are large molecule drugs that do not cross the blood-brain barrier. The BBB-penetration of enzyme therapeutics is enabled by re-engineering the recombinant enzyme as bi-functional IgG fusion proteins, wherein the IgG domain targets a specific endogenous receptor-mediated transporter system within the BBB, such as the human insulin receptor. Several bi-functional IgG-fusion proteins have

been engineered using a genetically engineered monoclonal antibody directed to the BBB HIR as the transport domain. First in-human clinical trials are in progress.

10:15 Coffee Break in the Exhibit Hall with Poster Viewing

11:00 Influence of BBB Transporters on the Delivery of Molecularly-Targeted Agents to Primary and Secondary Brain TumorsWilliam Elmquist, Pharm.D., Ph.D., Professor, Pharmaceutics, University of MinnesotaThis talk will focus on the issues surrounding effective drug delivery to the invasive cells in brain tumors, both primary and metastatic. Many of the newer targeted anti-cancer agents have impressive inhibitory action against signaling pathways that drive tumor growth. However, they have been ineffective in treating brain tumors. These molecularly-targeted inhibitors are often substrates for active efflux transporters at the BBB, and this delivery-limiting mechanism must be overcome before these inhibitors can be adequately tested in clinical trials.

11:30 Sorting of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain BarrierLudovic Collin, Laboratory Head, pRED RICB, F. Hoffmann-La RocheThe low endocytosis of brain endothelial cells (BECs) is believed to prevent delivery of immunoglobulins to the brain parenchyma. By using quantitative high-resolution microscopy, we found for the first time a steady-state accumulation of endogenous mIgG in intracellular vesicles in BECs. Our data challenge the established notion of low vesicular transport as a hallmark of the BBB.

12:00 pm Bridging Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Session Break

1:00 Coffee and Dessert in the Exhibit Hall with Poster Viewing

1:45 PLENARY KEYNOTE SESSION (Click here for details)

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing

4:15 Close of Conference

June 15-16, 2016 | Boston, MABlood-Brain Barrier

property-based

DRUG DESIGNin medicinal chemistryDriving Drug Discovery Success by Designing Right Physiochemical and Biophysical Properties

Fifth Annual

June 16-17, 2016 Westin Boston Waterfront Boston, MA

Stay on for...


http://www.worldpreclinicalcongress.com/Property-Based-Drug-Design/





Sponsorship, Exhibit & Lead Generation Opportunities

Podium Presentations—Available within Main Agenda!Showcase your solutions to a guaranteed, targeted audience. Package includes a 15- or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding, access to cooperative marketing efforts by CHI, and more.

Breakfast & Luncheon Podium PresentationsOpportunity includes a 30-minute podium presentation. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on early to secure your talk!

Invitation-Only VIP Dinner/Hospitality SuiteSponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects, helping you to make the most out of this invaluable opportunity. Evening will be customized according to sponsor’s objectives i.e.:

• Purely social• Focus group• Reception style• Plated dinner with specific conversation focus

ExhibitExhibitors will enjoy facilitated networking opportunities with qualified delegates. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

One-on-One MeetingsSelect your top prospects from the pre-conference registration list. CHI will reach out to your prospects and arrange the meeting for you. A minimum number of meetings will be guaranteed, depending on your marketing objectives and needs. A very limited number of these packages will be sold.

Looking for additional ways to drive leads to your sales team?

CHI’s Lead Generation Programs will help you obtain more targeted, quality leads throughout the year. We will mine our database of 800,000+ life science professionals to your specific needs. We guarantee a minimum of 100 leads per program! Opportunities include:

• Live Webinars• White Papers• Market Surveys • Podcasts and More!

CHI offers comprehensive sponsorship packages which include presentation opportunities, ex-hibit space, branding and networking with specific prospects. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company’s needs and budget. Signing on early will allow you to maximize exposure to qualified decision-makers.

For sponsorship and exhibit information, please contact:

Joseph Vacca, M.Sc. Associate Director, Business Development781-972-5431 | [email protected]

2016 Exhibitors & Sponsors (As of January 27, 2016)AbcamAdvanced Targeting Systems, Inc.AMRIAntiCancer Inc.Applied BioPhysics IncApplied StemCell, Inc.AxiogenesisBeckman Coulter Life SciencesBiomodels, LLCBiopta LtdBiopticonBruker Corporation CellectaCFD Research CorporationChampions OncologyCharles River ChemBridge Corporation Collaborative Drug Discovery (CDD)EnvigoExemplar GeneticsHera BioLabs HitGen LtdHurel CorporationIKKO-ZU Corporation ImageIQ, IncInSpheroThe Jackson LaboratoryKIYATEC Inc. Kuraray Co., Ltd.

MatTekMiltenyi Biotec Molecular Health Molecular Sensing, Inc. MR SolutionsNeuroScience AssociatesNeurotar LtdNortis, Inc. OncodesignOptibrium Organovo Inc. Promega Corporation ReachBio LLC Reaction Biology Corporation Schrödinger Scigilian Software Inc. SCIVAX Life Sciences, Inc. Simulations Plus, Inc. STEMCELL Technologies Surrogen Sygnature DiscoverySynthecon, Inc. SynthonixTaconic Biosciences Translational Cell SciencesTriangle Research Labs TriMetis Life Sciences VisualSonics

Please note, due to high demand and limited space, exhibit booths are being sold via sponsorship only!


mailto:jvacca%40healthtech.com?subject=





SHORT COURSES

Student FellowshipFull-time graduate students and Ph.D. candidates are encouraged to apply for the World Preclinical Congress Student Fellowship. Applications are due by March 25, 2016.

• Interested students must complete the below application for the 2016 Student Fellowship.

• Fellows are required to present a scientific poster. A poster title and abstract are due at the time of the application.

• All applications will be reviewed by the scientific review committee and the accepted students will be notified no later than April 13, 2016 if they were accepted for the 2016 Student Fellowship.

• Accepted 2016 Student Fellows will receive a discounted conference rate of $195*, which must be paid in full by April 29, 2016. Credit card information is requested at the time of the application and will be charged upon application approval.

• This fellowship is limited to 20 students and is for the Main Conference only*, June 15-17, 2016.

• All accepted 2016 Student Fellows will be asked to help promote the conference onsite at their college, and throughout their social media networks.

• Students not accepted for the 2016 Student Fellowship, can register at a discounted rate $295*, and will not be required to present a poster.

* This discounted rate cannot be combined with any other discounts for this event. Your discounted registration does not grant access to any of the short courses or pre-conference events. It also does not include hotel, travel or meals.

MEDIA PARTNERS

OFFICIAL MEDIA SPONSOR LEAD SPONSORING PUBLICATIONS SPONSORING PUBLICATIONS WEB PARTNERS






June 15-16, 2016 | Boston, MAJune 16, 2016 | Boston, MAPlenary Keynote Program

June 16, 1:45 - 3:00 pm

PLENARY KEYNOTE PRESENTATIONS:

Insights on Innovative Approaches to Transform Drug DiscoveryThis year’s Plenary Keynote Presentations feature two prominent thought-leaders who are playing an important role in innovating drug discovery. They share their experiences and their perspectives on what has changed and what can be changed to improve preclinical research, help translate preclinical findings to the clinic, and to foster effective communication and collaboration. Attendees will have an opportunity to ask questions and gain valuable insights from their learnings.

Keynote Speakers:Anthony J. Coyle, Ph.D., CSO and Senior Vice President, Centers for Therapeutic Innovation, Pfizer Inc.

James Wilson, M.D., Ph.D., Professor of Medicine and Pediatrics, Perelman School of Medicine; Director, Orphan Disease Center and Director, Gene Therapy Program, University of Pennsylvania

June 16, 3:00 - 3:30 pm

PLENARY KEYNOTE PANEL:

Insights on Innovative Technologies Enabling Preclinical ResearchThis year’s Plenary Keynote Panel features a group of technical experts from life science technology and service companies, who share their perspectives on various trends and tools that will likely change the way in which we traditionally approach preclinical drug discovery and development. Attendees will have an opportunity to ask questions and understand the impact of recent technical advances.

Panelists:Matt Gevaert, Ph.D., CEO and Co-Founder, KIYATECAmit Vasanji, Ph.D., CTO & CSO, ImageIQ Tim Robertson, Ph.D., CEO, Vium, Inc.



11 | World Preclinical Congress WorldPharmaCongress.com/Drug-Safety-Conference



June 15-16, 2016 | Boston, MAJune 16, 2016 | Boston, MAPlenary Keynote Program

Biographies

Dr. Anthony Coyle is the founding CSO of the Centers for Therapeutic Innovation (CTI) and is responsible for CTI’s strategy and scientific direction. Before leading CTI, Dr. Coyle was the Vice President and Global Head of Respiratory, Inflammation, and Autoimmunity Research at MedImmune Biologics, a Division of AstraZeneca. At MedImmune, Dr. Coyle advanced a biologic portfolio from discovery to Phase II in the areas of respiratory and

autoimmune diseases, specifically targeting lupus, asthma and COPD. Prior to his work at MedImmune, Dr. Coyle was Director of Research at Millennium Pharmaceuticals, where he led a group responsible for the identification of novel target genes, as well as for late stage lead optimization and delivery of both small-molecule and biologic development candidates. Dr. Coyle has been Associate Professor in the Department of Pathology and Experimental Therapeutics at McMaster University in Ontario since 1992. He has authored more than 200 manuscripts. Dr. Coyle holds a BSc (with honors) and a Ph.D. from Kings College, University of London. Dr. Coyle is a member of the scientific board for the Alliance for Lupus Research, the C4 NCATS consortium and the Boston Children’s Hospital Technology Fund Advisory Board.

Dr. James M. Wilson is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He then moved to Boston to do a residency in Internal Medicine at the Massachusetts General Hospital and continued his work in gene therapy at MIT. He

created the first and largest academic-based program in gene therapy after being recruited to University of Pennsylvania in 1993. He initially focused on the clinical translation of existing gene transfer technologies but soon redirected his efforts to the development of second and third generation gene transfer platforms; the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere. More recently, his laboratory discovered a family of viruses from primates that could be engineered to be very effective gene transfer vehicles. These so called “vectors” have become the technology platform of choice and have set the stage for the recent resurgence of the field of gene therapy. Dr. Wilson has also been active in facilitating the commercial development of these new gene therapy platforms through the establishment of several biotechnology companies. Throughout his career, the focus of Dr. Wilson’s research has been rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of metabolic disorders. Dr. Wilson has published over 550 papers, reviews, commentaries and editorials in the peer-reviewed literature and is an inventor on over 117 patents.

Dr. Matthew (Matt) Gevaert is the CEO of KIYATEC Inc., a life sciences company in Greenville, SC. KIYATEC specializes in ex vivo 3D cell culture and tissue systems that more accurately replicate in vivo human biology and function, with a focus on methods to accurately predict individual cancer patients’ response to drugs by culturing and treating live patient derived

primary cells. Dr. Gevaert co-founded the company and has served as CEO since 2007. Possessing a background which combines both business and technology, before his role at KIYATEC Dr. Gevaert led the commercialization of Clemson University’s biomedical and biotechnology intellectual property portfolio for nearly 5 years, working with both entrepreneurial start-ups and large, industry leading corporations. He has previous experience with Merck, 3M and Dow Chemical, and has been published in Science magazine and the journal of the US National Academy of Engineering. Currently he serves as a board member of SCBIO, the state of South Carolina’s life science industry organization, and a board member of NEXT, which provides entrepreneur services and infrastructure to high-growth ventures in Greenville and Upstate South Carolina. Dr. Gevaert grew up the fifth of six children on a farm in Ontario, Canada and graduated from the University of Waterloo with a bachelor’s degree in Applied Chemistry. He also holds a master’s degree and a doctorate in Bioengineering from Clemson University. He maintains current appointments as adjunct professor in the Clemson University Department of Bioengineering and as a lecturer in the Clemson MBA in Entrepreneurship & Innovation.

Dr. Amit Vasanji has over 17 years of experience with basic and clinical research image acquisition, processing, analysis, visualization and biomedical software engineering. He was the founder of Cleveland Clinic’s Biomedical Imaging and Analysis Center, and served as its Executive Director. During his tenure at the Cleveland Clinic, he authored over 50 publications — many in

high impact journals, participated in the writing of numerous federally funded grants, served as a consultant and/or co-investigator on many federal, state, corporate, and institutional grants, presented at national scientific meetings, and won various awards for innovation and service. Dr. Vasanji received a BS in Biomedical Engineering from the University of Miami, and a Ph.D. in biomedical engineering from Case Western Reserve University.

Dr. Timothy L. Robertson has more than 20 years experience in all stages of technology start-up process, from invention and product development to commercialization and monetization. Most recently he was VP of Product Applications at Proteus Digital Health, responsible for management of alliances with global pharmaceutical companies, core technology coordination and software development. He is the holder of more than

a dozen US patents and author of more than 40 scholarly publications in diverse fields. Tim has an A.B. in experimental physics and cosmology from Princeton University and Ph.D. in quantum physics from the University of California, Berkeley.



ADDITIONAL REGISTRATION DETAILSEach registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.To view our Substitutions/Cancellations Policy, go to www.healthtech.com/regdetailsVideo and or audio recording of any kind is prohibited onsite at all CHI events.

Complimentary news delivered to your inbox

A series of diverse reports designed to keep life science professionals informed of the salient trends in pharmaceutical technology, business, clinical development, and therapeutic disease markets.For a detailed list of reports, visit InsightPharmaReports.com, or contact Adriana Randall, [email protected], +1-781-972-5402.

Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit barnettinternational.com.

How to Register: [email protected] • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288

Please use keycode BBB F when registeringSubscribe to New Bulletins or the Weekly Update Newsletter at Bio-ITWorld.com

Clinical Trials to the Clinic, subscribe at ClinicalInformaticsNews.com



CONFERENCE PRICING

ALL ACCESS Commercial Academic, Government, Includes access to 2 Short Courses or 1 Symposium Hospital-affiliated and 2 Conferences/Training Seminar

After May 6, 2016 and on-site $3,199 $1,999

STANDARD PACKAGEIncludes access to 2 Conferences/Training Seminar, excludes Short Courses and Symposia

After May 6, 2016 and on-site $3,049 $1399

SINGLE CONFERENCE PRICINGIncludes access to 1 Conference/Training Seminar, excludes Short Courses and Symposia

After May 6, 2016 and on-site $2,049 $949

Conferences

June 15-16, 2016 June 16-17, 2016Blood-Brain Barrier Property-Based Drug Design in Medicinal Chemistry (Recommended Program)

SHORT COURSE PRICING*

Single Short Course $699 $399

Recommended Short Course

June 14, 2016, 3:30 – 6:30 pmSC10: Molecular Imaging of the Blood-Brain Barrier

Additional registration opportunities including 12 conferences, 2 symposia and 11 short courses can be found on the Registration page at WorldPreclinicalCongress.com

CONFERENCE DISCOUNTS - Poster, Alumni, and Group Discounts are available! Please see website for details.

If you are unable to attend but would like to purchase the World Preclinical Congress 2016 CD for $750 (plus shipping), please visit WorldPreclinicalCongress.com. Massachusetts delivery will include sales tax.

Pricing and Registration Information

http://www.healthtech.com/regdetails

http://www.insightpharmareports.com/

http://www.barnettinternational.com/

mailto:reg%40healthtech.com?subject=



New Understanding, Strategies and Tools for Delivering · 1:50 Low Intensity Pulsed Focused...

Documents

Transcript of New Understanding, Strategies and Tools for Delivering · 1:50 Low Intensity Pulsed Focused...